An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs Aldoxorubicin (Primary) ; Ifosfamide; Mesna
- Indications Chondrosarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors CytRx Corporation
- 07 Jun 2018 According to a CytRx Corporation media release, pooled data from this and other study (700214726) were presented at the American Society of Clinical Oncology 2018 Annual Meeting.
- 07 Jun 2018 Results presented in the CytRx Corporation media release.
- 05 Jun 2018 Results (n=52) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History